
Alpa Laboratories Ltd is Rated Strong Sell
2026-09-16 10:10:19Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 September 2026, providing investors with the latest insights into its performance and outlook.
Read full news article
Alpa Laboratories Ltd is Rated Strong Sell
2026-09-01 10:10:26Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article
Alpa Laboratories Ltd is Rated Strong Sell
2026-08-21 10:10:24Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article
Alpa Laboratories Ltd Valuation Shifts Signal Elevated Risk Amid Sector Challenges
2026-08-17 08:00:56Alpa Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters deteriorate significantly, prompting a downgrade to a Strong Sell rating. With its price-to-earnings (P/E) ratio rising to 32.77 and price-to-book value (P/BV) at 0.71, the stock now appears riskier compared to its historical averages and peer group, reflecting growing investor caution amid underwhelming returns and sector headwinds.
Read full news articleAre Alpa Laboratories Ltd latest results good or bad?
2026-08-14 19:50:26Alpa Laboratories Ltd's latest financial results for Q4 FY26 present a complex picture characterized by contrasting trends in profitability and revenue performance. The company reported a net profit of ₹1.38 crore, which reflects a sequential decline of 13.21% compared to the previous quarter. In terms of revenue, Alpa Laboratories generated ₹31.40 crore, marking an 8.09% increase from Q3 FY26 but a significant year-on-year decline of 21.34% from ₹39.92 crore in Q4 FY25. This revenue contraction is noteworthy as it follows a period of strong growth in the prior year, indicating potential challenges in sustaining sales momentum. Despite the revenue decline, the operating margin improved to 11.46%, the highest level in seven quarters, suggesting that the company has made strides in cost management. However, this margin expansion appears to be primarily driven by cost rationalization rather than an increase i...
Read full news article
Alpa Laboratories Ltd Reports Sharp Decline in Quarterly Financial Performance Amid Negative Trend Shift
2026-08-14 11:00:11Alpa Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a significant deterioration in its recent quarterly financial performance. The company’s latest results for June 2026 reveal a marked decline in revenue, profitability, and key return metrics, signalling a shift from a previously flat to a negative financial trend. This downturn comes amid broader sector pressures and contrasts sharply with benchmark indices such as the Sensex.
Read full news article
Alpa Laboratories Ltd is Rated Sell
2026-08-10 10:10:03Alpa Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 August 2026, providing investors with an up-to-date view of the company’s performance and outlook.
Read full news articleWhen is the next results date for Alpa Laboratories Ltd?
2026-08-05 23:19:06The next results date for Alpa Laboratories Ltd is scheduled for 14 August 2026....
Read full news article
Alpa Laboratories Ltd is Rated Sell
2026-07-30 10:10:03Alpa Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 30 July 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Read full news articleAnnouncement under Regulation 30 (LODR)-Change in Management
07-Sep-2026 | Source : BSEAppointment of Mrs. Radhika Biyani as an Independent Director.
Fixes Book Closure For The Purpose Of AGM.
07-Sep-2026 | Source : BSEIntimation of Book Closure for the Purpose of 38th AGM.
Reg. 34 (1) Annual Report.
07-Sep-2026 | Source : BSEAnnual Report for the Financial Year Ended March 312026
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available






